European Companies Search Engine
EU funding (€3,694,634): Multi-modal Optical Diagnostics for Ocular and Neurodegenerative Disease Hor1 Nov 2016 EU Research and Innovation programme "Horizon"
Overview
Text
Multi-modal Optical Diagnostics for Ocular and Neurodegenerative Disease
The rising life expectancy of EU citizens is creating a dramatic increase in age-related degenerative diseases and associated healthcare costs. The MOON Project (Multi-modal Optical Diagnostics for Ocular and Neurodegenerative Disease) meets this societal challenge by applying photonics to diagnose age-related diseases of the eye and central nervous system. Consistent with the ICT-29-2016: Photonics KET 2016 Work Program, MOON will design and build a multi-band, multimodal and functional imaging platform combining label-free molecularly sensitive Raman spectroscopy with high speed and high-resolution Optical Coherence Tomography (OCT), for in-depth diagnostics of ocular and neurodegenerative diseases. MOON will enhance OCT – already the gold standard of retinal imaging - through the development of a disruptive laser technology that enables wide-field structural and functional imaging. MOON will establish a reference database for molecular biomarkers of addressed diseases that enables, for the first time, in-depth molecular-specific diagnosis of retinal diseases and neurodegenerative pathologies based on Raman spectroscopy. The MOON system will be validated in vivo in a clinical setting through close collaboration between clinicians and commercial partners. The clinical validation will establish the diagnostic accuracy of the multi-modal platform, while also verifying the ease-of-use needed for widespread adoption. MOON is driven by unmet medical user needs in diagnostic imaging with a clear business case addressing the highly promising ophthalmic market of early and in-depth molecularly sensitive diagnostics of retinal and neurodegenerative diseases. The three industrial partners cover the complete value/supply chain. MOON aims to bridge the gap between research and product development, thereby expediting the commercialization of the MOON technologies, strengthening the participating companies, and creating a competitive advantage for the European photonics market.
Funded Companies:
| Company name | Funding amount |
| CARL ZEISS AG | €680,620 |
| Horiba France SAS | €512,500 |
| INNOLUME GmbH | €594,500 |
| LEIBNIZ-INSTITUT FUER PHOTONISCHE TECHNOLOGIEN e. V. | €583,500 |
| Medizinische Universitaet Wien | €812,702 |
| NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO | €510,812 |
Source: https://cordis.europa.eu/project/id/732969
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "CARL ZEISS AG - EU funding (€3,694,634): Multi-modal Optical Diagnostics for Ocular and Neurodegenerative Disease"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
